Showing results (31-40 of 217) with videos related to

Sort By:
Pageof 22
Lupus Science & Medicine|July 24, 2021
Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)Sarah Dyball, Sophie Collinson, Emily Sutton, et al.
Autoimmunity Reviews|November 8, 2017
Vitamin D and systemic lupus erythematosus - The hype and the hopeYehuda Shoenfeld, Roberto Giacomelli, Shir Azrielant, et al.
Clinical and Experimental Rheumatology|January 12, 2013
Serum cystatin C is independently associated with renal impairment and high sensitivity C-reactive protein in systemic lupus erythematosusChristine Chew, Philip W Pemberton, Awal Al-M Husain, et al.
Arthritis Research & Therapy|July 29, 2021
Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory modelsJohn A Reynolds, Jennifer Prattley, Nophar Geifman, et al.
Autoimmunity|November 28, 2024
High throughput multiplex immunoassays stratify patients according to symptom burden across the anti-Ro positive systemic autoimmune rheumatic disease spectrumSarah Dyball, Rudresh Shukla, Anastasia-Vasiliki Madenidou, et al.
The Lancet. Rheumatology|January 22, 2024
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal studyMia Rodziewicz, Sarah Dyball, Mark Lunt, et al.
Seminars in Arthritis and Rheumatism|January 7, 2024
Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review updateMia Rodziewicz, Claudia Mendoza-Pinto, Sarah Dyball, et al.
Lupus Science & Medicine|January 13, 2023
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trialsIan N Bruce, Ronald F van Vollenhoven, Konstantina Psachoulia, et al.
Annals of the Rheumatic Diseases|April 14, 2019
Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changesMichelle Barraclough, Shane McKie, Ben Parker, et al.
Clinical and Experimental Rheumatology|January 9, 2013
Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotectiveSarah K Heathfield, Benjamin Parker, Leo A H Zeef, et al.
Pageof 22